FindTrial
Sign In

The safety and efficacy of micro-invasive glaucoma surgery (MIGS) for secondary glaucoma following congenital cataract surgery

The safety and efficacy of micro-invasive glaucoma surgery (MIGS) for secondary glaucoma following congenital cataract surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057245
Enrollment
Unknown
Registered
2022-03-04
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma following congenital cataract surgery

Interventions

None listed

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age: 21 mmHg when the maximum dose of local IOP drugs was used; (2) Other anti-glaucoma surgeries have been performed, and IOP>21mmHg with or without local IOP drugs; (3) Children cannot tolerate drugs; 5. The parents of the child signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Unable to return to the hospital on time to complete the follow-up and related examinations; 2. Complicated with other eye diseases, such as uveitis, congenital iris abnormality, eye trauma, etc.; 3. Have a history of serious systemic diseases: congenital heart disease, rheumatic immunity, kidney disease and digestive system diseases.

Design outcomes

Primary

MeasureTime frame
intraocular pressure;—

Secondary

MeasureTime frame
Refractive status;—

Countries

China

Contacts

Public ContactWeirong Zhang

Zhongshan Ophthalmic Center, Sun Yat-sen University

chenwrq@aliyun.com+86 13501518370

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026